First European Patient Enrolled in ONL Therapeutics' Phase 2 GALAXY Trial for Geographic Atrophy ONL Therapeutics marks a significant milestone with the enrollment of its first European patient in the Phase 2 GALAXY trial for treating geographic atrophy linked to dry AMD.

First European Patient Enrolled in ONL Therapeutics' Phase 2 GALAXY Trial for Geographic Atrophy #None #Switzerland #Geographic_Atrophy #ONL_Therapeutics #Xelafaslatide